Related Experiment Videos
Cytotoxic activity of human pulmonary alveolar macrophages
Abstract:
The functions of human pulmonary alveolar macrophages (PAMs) have been relatively little studied compared with those of their circulating counterparts, blood monocytes. This study examined the ability of human PAMs to kill primary human tumor cell cultures and control normal fibroblasts in vitro. PAMs were derived by bronchial lavage from patients with lung cancer of various histological types and stages, patients with acute or chronic noncancerous pulmonary disorders, and subjects with a presumed illness who proved to be normal. After extensive washing, the PAMs were cocultured with [3H]proline-labeled tumor cells, principally lung cancers and melanomas, at various effector:target ratios for 60 hr. Cytotoxicity was measured by comparing radioactivity associated with the remaining adherent tumor cells cultured in the presence or absence of PAMs. Twenty-eight of 42 preparations of PAMs from 42 individuals were cytotoxic to one or more short-term primary tumor cultures. All 28 specimens from patients with lung cancer or chronic pulmonary disease were cytotoxic; all of the 14 PAM preparations lacking cytotoxicity were from individuals with acute pulmonary disorders or who were proved free of pulmonary disease. PAMs were cytotoxic even at effector:target ratios of 2.5:1 or 1.25:1. Fibroblasts were unaffected at any ratio. Sarcoidosis patients in remission had noncytotoxic PAMs, whereas the disease in relapse was characterized by cytotoxic PAMs. Serial study of 2 patients confirmed a loss of reactivity during remission. Smoking did not correlate with the presence or absence of spontaneous cytotoxicity and did not influence the degree of cytotoxicity in "reactors." Partially purified alpha-interferon enhanced the killing of cytotoxic PAMs in 10 of 21 instances but did not induce cytotoxicity in 9 tests on nonreactive PAMs. We conclude that human PAMs from patients with lung cancer or chronic pulmonary diseases, including active sarcoidosis, were cytotoxic to several recently explanted tumor cell cultures. PAMs from acute pulmonary dysfunctions and those from patients with inactive sarcoidosis were not spontaneously cytotoxic.
Insights
Human pulmonary alveolar macrophages (PAMs) from patients with lung cancer or chronic lung diseases, including active sarcoidosis, demonstrated significant tumor cell killing in vitro. PAMs from acute conditions or inactive sarcoidosis lacked this cytotoxic function.
Area of Science:
- Immunology
- Cell Biology
- Oncology
Background:
- Human pulmonary alveolar macrophages (PAMs) functions are less understood than circulating monocytes.
- Investigating PAMs' anti-tumor capabilities is crucial for understanding lung immunity.
Purpose of the Study:
- To assess the in vitro cytotoxic potential of human PAMs against primary tumor cell cultures.
- To compare PAMs' activity in patients with lung cancer, chronic pulmonary disorders, acute pulmonary disorders, and healthy individuals.
Main Methods:
- Human PAMs were isolated via bronchial lavage from diverse patient groups.
- PAMs were co-cultured with [3H]proline-labeled tumor cells (lung cancer, melanoma) and normal fibroblasts.
- Cytotoxicity was quantified by measuring residual radioactivity of adherent tumor cells.
Main Results:
- Twenty-eight of 42 PAM preparations exhibited cytotoxicity against tumor cells.
- PAMs from lung cancer and chronic pulmonary disease patients were cytotoxic, unlike those from acute conditions or healthy controls.
- Cytotoxicity was observed at low effector:target ratios (2.5:1, 1.25:1); fibroblasts remained unaffected.
- Active sarcoidosis correlated with cytotoxic PAMs, while remission showed non-cytotoxic PAMs.
Conclusions:
- Human PAMs from patients with lung cancer and active chronic pulmonary diseases possess spontaneous in vitro anti-tumor activity.
- PAMs from acute pulmonary conditions or inactive sarcoidosis lack this cytotoxic function.
- These findings highlight the differential functional states of PAMs in various lung pathologies.